BIOMARK DIAGNOSTICS TARGETS RESPONSE TO TREATMENT APPLICATION WITH ITS LIQUID BIOPSY PLATFORM
Vancouver, British Columbia – (February 8, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Use of Amantadine in the Evaluation of Response to Chemotherapy in Lung Cancer – a Pilot Study” has been published in the peer-reviewed journal Future Science OA. Rashid A. Bux, […]
